Research Perspectives:

Bone marrow adipocytes provide early sign for progression from MGUS to multiple myeloma

Bilal M. El-Masri, Benedeta Leka, Fatima Mustapha, Michael Tveden Gundesen, Maja Hinge, Thomas Lund, Thomas L. Andersen _, Marta Diaz-delCastillo _ and Abbas Jafari _

PDF  |  Full Text  |  How to cite  |  Press Release

Oncotarget. 2024; 15:20-26. https://doi.org/10.18632/oncotarget.28548

Metrics: PDF 674 views  |   Full Text 2161 views  |   ?  


Bilal M. El-Masri1,2, Benedeta Leka3, Fatima Mustapha4, Michael Tveden Gundesen5, Maja Hinge6, Thomas Lund5, Thomas L. Andersen1,2,4,7, Marta Diaz-delCastillo1,4 and Abbas Jafari3

1 Danish Spatial Imaging Consortium (DanSIC)

2 Department of Clinical Research, Molecular Bone Histology (MBH) Lab, University of Southern Denmark, Odense, Denmark

3 Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark

4 Department of Forensic Medicine, Molecular Bone Histology (MBH) Lab, University of Aarhus, Aarhus, Denmark

5 Department of Hematology Odense University Hospital, Odense, Denmark

6 Department of Hematology, Lillebaelt Hospital, Vejle, Denmark

7 Department of Pathology, Odense University Hospital, Odense, Denmark

Correspondence to:

Abbas Jafari, email: [email protected]
Marta Diaz-delCastillo, email: [email protected]
Thomas L. Andersen, email: [email protected]

Keywords: multiple myeloma; MGUS; bone marrow adipocyte

Received: October 13, 2023     Accepted: December 28, 2023     Published: January 16, 2024

Copyright: © 2024 El-Masri et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Multiple Myeloma (MM) is the second most common hematological malignancy and is characterized by clonal expansion of malignant plasma cells in the bone marrow. In spite of recent advances in the field of MM, the disease has remained incurable. MM is preceded by a premalignant state known as monoclonal gammopathy of undetermined significance (MGUS), with a risk of progression to MM of 1% per year. Establishing a scalable approach that refines the identification of MGUS patients at high risk of progression to MM can transform the clinical management of the disease, improve the patient’s quality of life, and will have significant socioeconomic implications. Here, we provide evidence that changes in the bone marrow adipose tissue (BMAT) provide an early sign for progression from MGUS to MM. We employed AI-assisted histological analysis of unstained bone marrow biopsies from MGUS subjects with or without progression to MM within 10 years (n = 24, n = 17 respectively). Although the BMAT fraction was not different between the two groups, bone marrow adipocyte (BMAd) density was decreased in MGUS patients who developed MM, compared to non-progressing MGUS patients. Importantly, the distribution profile for BMAd size and roundness was significantly different between the two groups, indicating a shift toward increased BMAd size and roundness in MGUS patients who developed MM. These early changes in the BMAT could serve as valuable early indicators for the transition from MGUS to MM, potentially enabling timely interventions and personalized treatment strategies. Finally, the AI-based approach for histological characterization of unstained bone marrow biopsies is cost-effective and fast, rendering its clinical implementation feasible.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 28548